Efficiency of Aurotaz-P (Piperacillin/Tazobactam) in Severe Nosocomial Intraabdominal Infections in Comparison with Carbapenems
Objective of this work - to compare efficiency of empiric antibacterial therapy by Aurotaz-P and mepenam in treatment for nosocomial intraabdominal infections. Materials and Methods. We have examined 60 patients treated at the Kharkiv municipal emergency and immediate care hospital named after prof. A.I. Meschaninov from 2013 to 2014. Against the background of conventional intensive therapy, 29 patients (group 1) as antibacterial therapy received Aurotaz-P 4.5 g by intravenous infusion every 8 hours, 31 patients (group 2) - mepenam 1 g by intravenous infusion every 8 hours. The age of patients ranged from 20 to 71 years (38.2 ± 7.9 years), there were 38 men (63.3 %). Duration of treatment was 7 days. Results and Discussion. We have allocated 55 strains of microorganisms from the abdominal content. Gram-negative microflora dominated. In most cases, the flora was sensitive both to Aurotaz-P and to mepenam, although one of the strains (Staphylococcus aureus) appeared insensitive to mepenam. During the treatment, positive bacteriological effect was achieved in all patients in group 1 and in 90.3 % of patients in group 2. In 2 patients of group 2 we observed persistence of the pathogen (Staphylococcus aureus), the positive effect in them was achieved after administration of Aurotaz-P. Complete elimination of the pathogen was achieved in 68.97 % of patients in group 1 and in 54.8 % of patients in group 2, the expected one - respectively in 31.03 and 38.7 %. Positive clinical efficacy was achieved in 28 (96.6 %) patients in group 1 (25 - recovery, 3 - improvement) and in 23 (74.1 %) patients in group 2 (18 - recovery, 5 - improvement). Conclusions. Combined antimicrobial agent Aurotaz-P has a broad spectrum of activity against Gram-positive and Gram-negative bacteria and anaerobes. Our data indicate that during the treatment of patients with peritonitis, Aurotaz-P at a dose of 4.5 g every 8 hours in no way inferior mepenam at a dose of 1.0 g every 8 hours. On the basis of our research we can recommend Aurotaz-P to implementation into the practice of healthcare as the drug of choice for empirical treatment for intraabdominal infections due to the high clinical efficacy and high safety profile.